Drug companies have overlooked patients who don’t respond to HIV meds
There are tens of thousands of these non-responders in the U.S., whose low CD4 numbers put them at much higher risk of heart attacks, stroke, cancers, secondary infections such as tuberculosis, and death. And yet, drug companies and researchers aren’t actively pursuing new treatments that would boost their immunity, leaving people like Vergel feeling neglected.Read more
ABIA concerned after the exoneration of HIV/AIDS and STIs Department Director
In view of recent changes in the Ministry of Health’s Department of Surveillance, Prevention and Control of STIs, HIV and Viral Hepatitis of the Ministry of Health, ABIA wishes to express concerns regarding the sustainability STIs and HIV/AIDS control policies.Read more
HIV in the Philippines: why it must act fast to control growing epidemic, advocacy groups lead the way
While many countries, including in Southeast Asia, have seen a fall in new HIV infections, the Philippines has seen a sharp rise.
Bureaucracy, a conservative society and the Catholic Church are the main stumbling blocks to effective action.
Elizabeth Warren is trying to break up Big Pharma “cartels” by letting the government make generic drugs
Democratic Sen. Elizabeth Warren, who’s widely expected to run for president in 2020, introduced a bold piece of legislation Tuesday that seeks to break up generic drug “cartels” by allowing the U.S. government to manufacture its own drugs.Read more
Gilead legal action blocks delivery of generic medicine for Hep C treatment in Brazil
Twelve trucks are stationed in the Ministry of Health’s warehouse, in Sao Paulo, with shipments that would allow for the treatment of 15,000 patients who have been waiting for these medicines for a year. The reason is that Gilead Sciences blocked the delivery of hep C treatment generic medicines, which were purchased on an emergency call for more severe patients. The Court upheld Gilead’s claim that the generic drug value is insufficient. Meanwhile, Gilead has already applied for the medicine’s patent.Read more
Ten reasons people stop attending HIV care in Zambia
Patient-provider relationships are strained by poor working conditions and rigid application of one-size-fits-all models of care, according to an in-depth investigation of why people with HIV drop out of HIV treatment services in Zambia, recently published in BMJ Global Health.Read more
High-level support for PEPFAR, with budget cut proposals looming
The United States Congress passed a bill to reauthorize the President’s Emergency Plan for AIDS Relief and its mandate will be extended through 2023 when President Donald Trump signs the legislation into law, which is expected to happen soon.Read more
Activists demand the president-elect to defend the Universal Health System and to maintain the current AIDS policy
Congressman Jair Messias Bolsonaro, 63 years old, was elected on Sunday (28) Brazil’s new president. AIDS activists told the National AIDS Agency what they expect from Bolsonaro in regards to the country’s policy. And they were unanimous: the guarantee of access to antiretroviral provided by the Universal Health System (SUS) and the maintenance of the current AIDS policy.Read more
Colombia. 3 years waiting for a Public Interest Declaration for Hep C medicines.
Just a few medicines are life-saving. Snake bite antivenoms. Antibiotics in specific cases. HIV medicines. And recently, hepatitis C Direct Accion Antivirals. No one could say that, if there is any restriction to any human been in need of any life-saving medicine, it is not a Public Interest Situation. It is not necessary to remember the shocking prices of Hep C medicines IN DEVELOPED COUNTRIES.Read more
WIPO conference an insult to people who died of AIDS
We have so much respect for intellectual property in South Africa that at present we grant patents without examining whether the patents are merited. Government has finally started a process to institute a patent examination system, but this will take time to get off the ground. For now, we continue to give away patents without scrutiny.Read more